Cradle provides an AI software platform for protein engineering that generates lab-ready protein candidates optimized across multiple properties such as binding affinity, specificity, activity, stability, and expression levels, using machine learning models trained exclusively on each customer's uploaded experimental data. The platform produces generation reports with predictive performance scores, supports full-plate optimization, and maintains privacy through custom organization-specific models. It serves biopharma and industrial biotech R&D teams, including a partnership with Novonesis to embed AI in innovation processes and a collaboration with Bayer for antibody discovery and optimization. Co-founded in 2021 by Stef van Grieken, Jelle Prins, Elise de Reus, Eli Bixby (CEO), and Harmen van Rossum, with key executives including Daniel (CTO), Sara (CCO), and Max (COO). Cradle raised €5.5 million seed funding in November 2022 led by Index Ventures, $24 million Series A in November 2023 led by Index Ventures, and $73 million Series B in December 2024 led by IVP. Headquarters are in Amsterdam, Netherlands, with an additional office in Zurich, Switzerland, teams in Boston and California, and a wet lab in Amsterdam.